The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome
OBJECTIVE: It remains unclear whether the low amount of SMPDL-3b required for rituximab binding is the cause of treatment resistance in patients with treatment-resistant nephrotic syndrome with advanced podocyte injury. Given the limited number of studies on the relationship between rituximab and SMPDL-3b, this study was conducted to assess whether SMPDL-3b levels in pretreatment renal biopsy specimens can be used to predict the clinical effectiveness of immunosuppressive drugs, especially rituximab, in children with nephrotic syndrome.
METHODS: Kidney biopsy specimens from 44 patients diagnosed with idiopatic nephrotic syndrome were analyzed using immunohistochemical staining with an anti-SMPDL-3b antibody and real-time polymerase chain reaction (PCR) for SMPDL-3b mRNA expression.
RESULTS: We showed that SMPDL-3b mRNA expression and anti-SMPDL-3b antibody staining did not differ significantly between the patient groups with different responses to immunosuppressive therapies.
CONCLUSION: Our results suggest that SMPDL-3b may actually be an indicator of disease progression rather than a marker for predicting response to a particular immunosuppressive agent.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Fetal and pediatric pathology - 42(2023), 6 vom: 11. Dez., Seite 936-949 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaya, Muhammet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 23.11.2023 Date Revised 23.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15513815.2023.2267683 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363116524 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363116524 | ||
| 003 | DE-627 | ||
| 005 | 20231226092651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15513815.2023.2267683 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363116524 | ||
| 035 | |a (NLM)37818552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaya, Muhammet |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2023 | ||
| 500 | |a Date Revised 23.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: It remains unclear whether the low amount of SMPDL-3b required for rituximab binding is the cause of treatment resistance in patients with treatment-resistant nephrotic syndrome with advanced podocyte injury. Given the limited number of studies on the relationship between rituximab and SMPDL-3b, this study was conducted to assess whether SMPDL-3b levels in pretreatment renal biopsy specimens can be used to predict the clinical effectiveness of immunosuppressive drugs, especially rituximab, in children with nephrotic syndrome | ||
| 520 | |a METHODS: Kidney biopsy specimens from 44 patients diagnosed with idiopatic nephrotic syndrome were analyzed using immunohistochemical staining with an anti-SMPDL-3b antibody and real-time polymerase chain reaction (PCR) for SMPDL-3b mRNA expression | ||
| 520 | |a RESULTS: We showed that SMPDL-3b mRNA expression and anti-SMPDL-3b antibody staining did not differ significantly between the patient groups with different responses to immunosuppressive therapies | ||
| 520 | |a CONCLUSION: Our results suggest that SMPDL-3b may actually be an indicator of disease progression rather than a marker for predicting response to a particular immunosuppressive agent | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Nephrotic syndrome | |
| 650 | 4 | |a SMPDL-3b | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Sphingomyelin Phosphodiesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.4.12 |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Girişgen, İlknur |e verfasserin |4 aut | |
| 700 | 1 | |a Yalçın, Nagihan |e verfasserin |4 aut | |
| 700 | 1 | |a Becerir, Tülay |e verfasserin |4 aut | |
| 700 | 1 | |a Şenol, Hande |e verfasserin |4 aut | |
| 700 | 1 | |a Gülten, Gülsün |e verfasserin |4 aut | |
| 700 | 1 | |a Yüksel, Selcuk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Fetal and pediatric pathology |d 2004 |g 42(2023), 6 vom: 11. Dez., Seite 936-949 |w (DE-627)NLM150461623 |x 1551-3823 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:6 |g day:11 |g month:12 |g pages:936-949 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15513815.2023.2267683 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 6 |b 11 |c 12 |h 936-949 | ||